Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
41
NDRA Quote, Financials, Valuation and Earnings
Last price:
$4.95
Seasonality move
:
5.28%
Day range:
$5.12 - $5.33
52-week range:
$2.90 - $11.96
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.26x
P/B ratio:
36.14x
Volume:
22K
Avg. volume:
92.9K
1-year change:
24.36%
Market cap:
$6.2M
Revenue:
--
EPS (TTM):
-$13.39
Analysts' Opinion
-
Consensus RatingENDRA Life Sciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $30.00, ENDRA Life Sciences, Inc. has an estimated upside of 464.97% from its current price of $5.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $30.00 representing 100% downside risk from its current price of $5.31.
Fair Value
-
According to the consensus of 1 analyst, ENDRA Life Sciences, Inc. has 464.97% upside to fair value with a price target of $30.00 per share.
NDRA vs. S&P 500
-
Over the past 5 trading days, ENDRA Life Sciences, Inc. has underperformed the S&P 500 by -2.11% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ENDRA Life Sciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ENDRA Life Sciences, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter ENDRA Life Sciences, Inc. reported revenues of --.
Earnings Growth
-
ENDRA Life Sciences, Inc. has grown year-over-year earnings for 14 quarters straight. In the most recent quarter ENDRA Life Sciences, Inc. reported earnings per share of -$2.10.
Enterprise value:
5.9M
EV / Invested capital:
8.50x
Price / LTM sales:
3.26x
EV / EBIT:
--
EV / Revenue:
2.86x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-1.16x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$164.1K
Return On Assets:
-192.72%
Net Income Margin (TTM):
--
Return On Equity:
-318.69%
Return On Invested Capital:
-265.94%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$282K | -$221.1K | -$164.1K | -$54K | -$39.4K | |
| Operating Income | -$12.4M | -$15.3M | -$8.4M | -$8.8M | -$1.4M | |
| EBITDA | -$12.1M | -$15.1M | -$8.3M | -$8.8M | -$1.3M | |
| Diluted EPS | -$4,894.03 | -$1,172.20 | -$13.39 | -$333.82 | -$2.10 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $14.5M | $11.6M | $6.4M | $5M | $1M | |
| Total Assets | $15.3M | $12.3M | $7.6M | $8.4M | $2M | |
| Current Liabilities | $1.6M | $1.7M | $2.2M | $814K | $800.3K | |
| Total Liabilities | $2.2M | $2.1M | $2.4M | $1.8M | $1.8M | |
| Total Equity | $13.2M | $10.2M | $5.2M | $6.6M | $171.4K | |
| Total Debt | $581.3K | $434.3K | $265.7K | $49.8K | $396.5K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$10.5M | -$8.1M | -$5.1M | -$1.7M | -$1.2M | |
| Cash From Investing | -$65.6K | -$10.5K | -$17.3K | -- | -- | |
| Cash From Financing | $5.8M | $9.5M | $1.2M | $1.7K | $149.5K | |
| Free Cash Flow | -$10.5M | -$8.1M | -$5.1M | -$1.7M | -$1.2M | |
NDRA
Sector
Market Cap
$6.2M
$28M
Price % of 52-Week High
44.4%
51.86%
Dividend Yield
0%
0%
Shareholder Yield
-28.38%
-1.4%
1-Year Price Total Return
24.36%
-19%
Beta (5-Year)
-0.330
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.67
200-day SMA
Buy
Level
$4.83
Bollinger Bands (100)
Sell
Level
4.48 - 6.18
Chaikin Money Flow
Sell
Level
-53.8M
20-day SMA
Sell
Level
$5.74
Relative Strength Index (RSI14)
Sell
Level
45.60
ADX Line
Sell
Level
15.15
Williams %R
Neutral
Level
-71.3235
50-day SMA
Sell
Level
$5.86
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-20
On Balance Volume
Neutral
Level
117.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-44.1421)
Sell
CA Score
(Annual)
Level (-13.989)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (17.2518)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ENDRA Life Sciences, Inc. engages in the development of medical devices for accurate liver fat measurement for use in metabolic disease detection and GLP-1 drug eligibility and management. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.
Stock Forecast FAQ
In the current month, NDRA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NDRA average analyst price target in the past 3 months is $30.00.
-
Where Will ENDRA Life Sciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that ENDRA Life Sciences, Inc. share price will rise to $30.00 per share over the next 12 months.
-
What Do Analysts Say About ENDRA Life Sciences, Inc.?
Analysts are divided on their view about ENDRA Life Sciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ENDRA Life Sciences, Inc. is a Sell and believe this share price will drop from its current level to $30.00.
-
What Is ENDRA Life Sciences, Inc.'s Price Target?
The price target for ENDRA Life Sciences, Inc. over the next 1-year time period is forecast to be $30.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NDRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ENDRA Life Sciences, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of NDRA?
You can purchase shares of ENDRA Life Sciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ENDRA Life Sciences, Inc. shares.
-
What Is The ENDRA Life Sciences, Inc. Share Price Today?
ENDRA Life Sciences, Inc. was last trading at $4.95 per share. This represents the most recent stock quote for ENDRA Life Sciences, Inc.. Yesterday, ENDRA Life Sciences, Inc. closed at $5.31 per share.
-
How To Buy ENDRA Life Sciences, Inc. Stock Online?
In order to purchase ENDRA Life Sciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get NDRA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NDRA
Sector
P/E ratio
--
24.31x
PEG ratio
0.00x
-0.01x
P/B ratio
36.14x
1.83x
Price / LTM sales
3.26x
1.60x
Growth Metrics
NDRA
Sector
Revenue growth
--
4.6%
Earnings growth
99.37%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$1.95
-$0.20
Profitability
NDRA
Sector
Profitability FY 2024
-$206.2K
$3.5M
Return on invested capital
-265.94%
-31.66%
Return on assets
-192.72%
-27.84%
Return on equity
-318.69%
-37.28%
Earnings Date
Last Earnings Date
Dec
17
Next Earnings Date
Dec
17
Estimated Next Earnings Date
Mar
18
Balance Sheet
NDRA
Sector
Total cash
$794K
$26.8M
Short term investments
--
$26M
Total assets
$4.5M
$78.7M
Long term debt
$396.5K
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 18.2% over the past day.
Sell
33
ZBIO alert for Dec 16
Zenas BioPharma, Inc. [ZBIO] is up 13.35% over the past day.
Sell
38
HUT alert for Dec 16
Hut 8 Corp. [HUT] is up 3.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
